Drug delivery of temozolomide for systemic based treatment of cancer
The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.
1. A pharmaceutical composition, comprising:
a therapeutically effective amount of a polymalic acid-based nanoconjugate of temozolomide (TMZ), wherein the polymalic acid-based nanoconjugate of TMZ is a compound of the formula:
or a derivative thereof, wherein the derivative is an imidazotetrazine compound having antitumor activity; and
a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , wherein the polymalic-acid based nanoconjugate of TMZ is a compound of the formula:
or a derivative thereof, wherein the derivative is an imidazotetrazine compound having antitumor activity.